Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04305613 · ClinicalTrials.gov registry record
Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy
A clinical trial of Radiation Toxicity and Cardiotoxicity, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- 221
- Enrollment target
- 8
- Study locations
NCT04305613: Active study of Radiation Toxicity and Cardiotoxicity, sponsored by Abramson Cancer Center at Penn Medicine.
NCT04305613 is a study of Radiation Toxicity and Cardiotoxicity that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 221 participants, below the 455-participant average among 12 other Radiation Toxicity trials with a reported enrollment target (51% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04305613, a study of Radiation Toxicity and Cardiotoxicity, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- 221 participants
- Enrollment target
- 8
- Study locations
Study Summary
This observational cohort will evaluate the cardiovascular effects of chemoradiation used to treat locally advanced, non-small cell lung cancer. Patients will be enrolled prior to the start of therapy and followed during and for at least 2 years after therapy with echocardiograms, nuclear stress tests, blood sampling, and quality of life surveys.
Primary Outcome
Change in hsCRP from baseline
Conditions Studied
Interventions
- OTHER Chemoradiation
Study Locations (8)
Pennsylvania
- Lancaster General Hospital - Lancaster
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
- Chester County Hospital - West Chester
Alabama
- University of Alabama - Birmingham
Massachusetts
- The Brigham and Women's Hospital - Boston
Missouri
- Washington University School of Medicine - St Louis
New Jersey
- Rutger's University / Cancer Institute of New Jersey - New Brunswick
New York
- Montefiore Medical Center - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 221 participants |
| Start Date | 2020-09-14 |
| Est. Completion | 2030-12 |
What the registry record for NCT04305613 still lists
NCT04305613 is an observational study that tracks outcomes without assigning an intervention. The registered 221 participants enrollment target is mid-sized for trials with a published cap, below the 455-participant average among 12 other Radiation Toxicity trials with a reported enrollment target (51% lower).
The record links to 4 conditions, with Radiation Toxicity appearing as the primary indexed condition, and to 1 intervention - of which Chemoradiation is the first listed.
NCT04305613 lists 8 locations in 6 states (Pennsylvania, Alabama, Massachusetts).
Frequently Asked Questions
What is clinical trial NCT04305613 about?
NCT04305613 is a clinical study titled "Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy". This observational cohort will evaluate the cardiovascular effects of chemoradiation used to treat locally advanced, non-small cell lung cancer. Patients will be enrolled prior to the start of therapy and followed during and for at least 2 years after therapy with echocardiograms, nuclear stress tes...
What is the current status of trial NCT04305613?
This trial is currently active not recruiting. The enrollment target is 221 participants. The study started on 2020-09-14. Estimated completion is 2030-12.
What conditions does trial NCT04305613 study?
This clinical trial studies the following conditions: Radiation Toxicity, Cardiotoxicity, Lung Cancer Stage II, Lung Cancer Stage III.
What interventions are being tested in trial NCT04305613?
The interventions under investigation include: Chemoradiation (OTHER).
Who is sponsoring clinical trial NCT04305613?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04305613 being conducted?
This trial has 8 study locations across Alabama, Massachusetts, Missouri, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Radiation Toxicity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04305613's enrollment target sits among peer trials
221 4th of 12 higher than 9 of 12 other Radiation Toxicity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Radiation Toxicity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pre-Rehabilitation for Female Patients Undergoing Pelvic Radiotherapy
RECRUITING · NA
-
A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
RECRUITING · Early Phase 1
-
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
RECRUITING · Phase 1
-
Metabolomic and Epigenetic Profiling of Bodyfluids From Lung and Brain Cancer Receiving Radiation Therapy
ACTIVE NOT RECRUITING
-
Predicting the Risk of Failure in Patients Undergoing Radiation Therapy for Localized Prostate Cancer
ACTIVE NOT RECRUITING
-
Radiation Therapy Plus Amifostine in Treating Patients With Primary Prostate Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03170440 · 221 participants · NA
Non-invasive Nerve Stimulation for PTSD and Sleep
- NCT04939610 · 222 participants · Phase 1
A Study of 177Lu-FAP-2286 in Advanced Solid Tumors
- NCT05424783 · 222 participants
MRI And GPS Informing Choices for Prostate Cancer Treatment (MAGIC)
- NCT05568264 · 222 participants · NA
Effects of a Physical Therapy Intervention on Motor Delay in Infants Admitted to a Neonatal Intensive Care Unit
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI